161 related articles for article (PubMed ID: 35582405)
1. Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer.
Wang YY; Li L; Liu XJ; Miao QF; Li Y; Zhang MR; Zhen YS
J Pharm Anal; 2022 Apr; 12(2):232-242. PubMed ID: 35582405
[TBL] [Abstract][Full Text] [Related]
2. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
[TBL] [Abstract][Full Text] [Related]
3. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
[TBL] [Abstract][Full Text] [Related]
4. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.
He S; Zhao C; Tao H; Sheng W; Gao R; Liu X; Zhen Y
Drug Deliv; 2022 Dec; 29(1):1243-1256. PubMed ID: 35416106
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation.
Tao HY; He SM; Zhao CY; Wang Y; Sheng WJ; Zhen YS
Int J Biol Macromol; 2023 Jan; 226():1088-1099. PubMed ID: 36435475
[TBL] [Abstract][Full Text] [Related]
6. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
7. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
8. An arginine-rich cell penetrating peptide contained anti-gelatinase scFv-LDM fusion protein shows potent antitumor efficacy in pancreatic cancer.
Zhong G; Xu Z; Yang R; Zhang S; Li L; Wu M; Liu H; Zhen Y
J Cancer; 2018; 9(4):674-682. PubMed ID: 29556325
[TBL] [Abstract][Full Text] [Related]
9. Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma.
Liu WJ; Zhu KL; Xu J; Wang JL; Zhu H
Lab Invest; 2018 Dec; 98(12):1538-1548. PubMed ID: 30206309
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
[TBL] [Abstract][Full Text] [Related]
11. Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy.
Zhong GS; Wu MN; Guo XF; Xu ZS; Zhang SH; Zhen YS
Oncol Lett; 2013 Apr; 5(4):1183-1188. PubMed ID: 23599760
[TBL] [Abstract][Full Text] [Related]
12. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.
Guo XF; Zhu XF; Yang WC; Zhang SH; Zhen YS
PLoS One; 2014; 9(3):e92986. PubMed ID: 24664246
[TBL] [Abstract][Full Text] [Related]
13. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy.
Xu J; Du Y; Liu XJ; Zhu BY; Zhang SH; Li L; Li Y; Wang XF; Shan CK; Wang RQ; Zhen YS
Pharmacol Res; 2017 Dec; 126():66-76. PubMed ID: 28392461
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
[TBL] [Abstract][Full Text] [Related]
15. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
[TBL] [Abstract][Full Text] [Related]
16. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
17. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
[TBL] [Abstract][Full Text] [Related]
18. The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent efficacy against pancreatic cancer.
Du YB; Wang XF; Liu XJ; Li Y; Miao QF; Jiang M; Sheng WJ; Zhen YS
Biochem Pharmacol; 2022 Jul; 201():115057. PubMed ID: 35489393
[TBL] [Abstract][Full Text] [Related]
19. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
[TBL] [Abstract][Full Text] [Related]
20. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]